Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India

Boehringer IngelheimBoehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world. Many diseases are spread by not washing hands, as a result of lack of knowledge, very limited access to hygiene products, awareness and missing access to clean water: According to UNICEF, diarrhea remains the second largest cause of mortality for children aged under-five globally. Every year, 1.4 million children die from diarrheal diseases due to a lack of safe water, bad sanitation and basic hygiene.

The Boehringer Ingelheim initiative called ‘Elephants’ was launched end of September 2018 in Coimbatore within the Indian state of Tamil Nadu with a training course for 60 village inhabitants on soap production. The objective is to enable a healthier living in the villages and creating simultaneously an income source for the communities by self-managed soap micro-enterprises. Additionally, the project aims to create business knowledge and logistics skills amongst the participants so that they will be able to independently market their homemade soaps in future. Another core task of this initiative is to increase awareness of infections with communicable diseases due to bad hygiene. The 'Elephants' project is run by Boehringer Ingelheim employees who volunteered to engage in company-sponsored projects in India through the company's initiative Making More Health.

"We know from the western world that there is no health without wealth. This experience seems unknown, unmet or unsolved in our project area. In order to solve this problem we have to combine health with solutions that create an income," explains Manolis Mitakis, Pharmacist and Head of Communications & Public Affairs of the Greek subsidiary of Boehringer Ingelheim, who travelled to India, involved in the Making More Health Executive in Residence Program.

The Boehringer Ingelheim long-term and global initiative Making More Health (MMH) aims to create a healthier world for individuals, communities and families. By supporting social entrepreneurs and social entrepreneurial thinking, MMH is looking for innovative solutions, which create social impact. Together with the local partner-NGO, the Karl Kübel Institute for Development Education and the German federal state Hessen toilets are built or renovated to increase hygiene among schoolchildren in the chosen territory in Tamil Nadu/ India. Education and awareness programs on hygiene help a lot that children can visit schools at a regular basis. However, awareness is only the first step to prevent diseases. The second step is to make sure that the knowledge leads to the right hygienic behavior and here soap can play a major role.

"Our MMH activities in India started in 2015 in close collaboration with local stakeholders. That's why we co- create with others, build kindergarten buildings and train kindergarten teachers on health awareness in the rural villages, provide toilets in schools and contribute actively to a hygiene campaign of one of our social entrepreneurs in our network. A two year health awareness program for tribal people including various health topics and digital trainings as well as safety trainings for daily life are also part of our activities. With teaching people skills and enabling them to create their own income we do a next step. We run regularly leadership weeks for our managers in our project area, close to Coimbatore - and we learn a lot: because understanding and talking to the local communities and organizations is important to develop solutions that are meeting the real needs and which are accepted," says Manuela Pastore, global lead of Making More Health.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Novartis research shows technology talent increasi…

Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing res...

GSK COVID-19 vaccine development collaboration wit…

GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiati...

Lilly begins world's first study of a potential CO…

Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This inve...

Sanofi invests to make France its world class cent…

Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in respon...

Low-cost dexamethasone reduces death by up to one …

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for C...

Super-potent human antibodies protect against COVI…

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus ...

Sanofi and Translate Bio expand collaboration to d…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to ...

AstraZeneca to supply Europe with up to 400 millio…

AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 milli...

Gilead announces results from Phase 3 Trial of rem…

Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label st...

Up to 45 percent of SARS-CoV-2 infections may be a…

An extraordinary percentage of people infected by the virus behind the ongoing deadly COVID-19 pandemic never show symptoms of the disease, according to the results of a ...

Bayer supports "The Challenge Initiative…

Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public...

Researchers identify potent antibody cocktail to t…

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail...